Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

tNIV Vaccine

Vaccine (Recombinant protein vaccine) · Immune activation, directed at Influenza A H1N1 hemagglutinin, Influenza A H3N2 hemagglutinin and Influenza B Victoria lineage hemagglutinin · developed by Novavax

Phase 3 Most advanced trial (none active)

NVAX Developer

1 Registered trials

What is tNIV Vaccine?

tNIV Vaccine is a trivalent nanoparticle influenza vaccine containing hemagglutinin antigens from influenza A (H1N1 and H3N2) and influenza B Victoria lineage strains, formulated with Matrix-M adjuvant. It is studied in COVID-19 and influenza.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Recombinant protein vaccine)
Targets: Influenza A H1N1 hemagglutinin (antigen), Influenza A H3N2 hemagglutinin (antigen), Influenza B Victoria lineage hemagglutinin (antigen)
Mechanism: Immune activation, directed at Influenza A H1N1 hemagglutinin, Influenza A H3N2 hemagglutinin and Influenza B Victoria lineage hemagglutinin
Pathways: immune_activation
Therapy area: Infectious disease
Developer: Novavax (NVAX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06291857	Phase 3	COVID-19	Completed	NVAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19

More from Novavax

CIC Vaccine Phase 3 EBOV GP Vaccine Phase 1 Fluzone HD Phase 2/3 ICC Vaccine Phase 1/2 NanoFlu Phase 3 NVX-CoV2372 Phase 2 NVX-CoV2373 Phase 3 NVX-CoV2515 Phase 3 NVX-CoV2540 Phase 3 NVX-CoV2601 Phase 2/3 NVX-CoV2705 Phase 3 qNIV Vaccine Phase 2

Sources

ClinicalTrials.gov NCT06291857

Updated Oct 3, 2026. Something wrong or missing? Report it on the NVAX page.

Follow NVAX, the company behind tNIV Vaccine

See NVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVAX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z